PeakXV Partners has sold its stake in La Renon Healthcare Private Limited to a consortium comprising Creador Group, White Oak Group, and Siguler Guff, marking one of the notable private equity transactions within India’s specialty pharmaceuticals segment this year.

As part of the deal, Creador Group invested approximately ₹800 crore in La Renon, reflecting sustained institutional interest in companies operating across chronic and specialty therapy areas.

Also Read: Tenneco Clean Air India Limited Raises ₹3,600 Crore in Strongly Subscribed IPO

The transaction underscores investor confidence in La Renon’s growth trajectory. The company, which ranks among India’s top 50 pharmaceutical companies, has built a strong portfolio in nephrology, critical care, neurology, and cardiac metabolism, sectors that continue to attract premium valuations due to high barriers to entry and rising demand.

The structure of the deal reflects a secondary sale by PeakXV, accompanied by fresh participation from White Oak and Siguler Guff.

Parties Involved

• Seller: PeakXV Partners

• Investors / Acquirers:

  • Creador Group

  • White Oak Group

  • Siguler Guff

• Target: La Renon Healthcare Private Limited

Legal Advisory

TT&A – Counsel to PeakXV Partners

TT&A acted for PeakXV, advising on the full transaction lifecycle, including due diligence, documentation, and negotiation.

Deal Team

• Dushyant Bagga, Partner

• Garvita Mehrotra, Managing Associate

• Prerna Raturi, Senior Associate

Veritas Legal – Counsel to Creador Group

Veritas Legal acted for Creador, advising on due diligence, drafting and negotiation of transaction documents, closing execution, and securing an unconditional CCI approval.

Corporate & Competition Team

• Manav Raheja, Senior Partner – Corporate

• Zenia Cassinath, Partner – Competition

• Swapnil Phadnis, Principal Associate

• Kapeesh Grover, Associate

• Aryan Mehta, Associate

• Ishan Mhapsekar, Associate

• Rahil Shah, Associate

• Abhay, Associate

• Aagam Shah, Associate

• Afrrin Advani, Associate

• Kritvi Kumar, Associate

• Dhruv Mehta, Associate

• Harshita Kushwah, Associate

The firm handled both corporate and regulatory aspects, including CCI notifications.

AZB & Partners – Counsel to Siguler Guff

AZB advised Siguler Guff on the investment.

Key Transaction Highlights

• PeakXV’s complete exit marks a significant portfolio rebalancing event for the fund.

• Creador’s ₹800 crore investment represents one of their largest commitments in Indian healthcare in recent years.

• The simultaneous involvement of White Oak and Siguler Guff signals broader institutional interest in specialty pharma.

• The transaction required multi-layered regulatory analysis, including competition law assessment.

• The deal reinforces consolidation trends in India’s mid-market pharmaceuticals sector.

Strategic Significance

For La Renon Healthcare

Access to new institutional capital strengthens its ability to accelerate expansion in chronic therapies, scale R&D infrastructure, invest in capacity enhancement, and deepen regional penetration in high-priority therapeutic segments.

For Investors

The acquisition aligns with long-term investment theses around:

• growing chronic disease burden in India,

• strong prescription-driven demand,

• stable cash flows from specialized portfolios.

La Renon’s focus areas—particularly nephrology and critical care—continue to attract strategic and financial investors due to limited competition and sustained market growth.

For PeakXV

The exit reflects the successful monetisation of a mature healthcare portfolio asset.

Why It Matters

This transaction is emblematic of rising investor appetite for mid-sized, high-margin pharmaceutical companies with specialised portfolios.
It also demonstrates:

• increasing competition among global investors for high-quality healthcare assets,

• the continued importance of regulatory expertise in large secondary deals, and

• the expanding role of private equity in shaping India’s specialty pharma landscape.

Also Read: JSW Paints Raises ₹3,300 Crore via Maiden NCD Issuance

For more legal deal updates and analysis, stay tuned to TheCourtroom.in

Disclaimer

This article is for informational purposes only and does not constitute legal or financial advice. Readers should consult professionals before making decisions